Albireo Pharma (NASDAQ:ALBO) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Monday, January 8th. The firm currently has a $33.00 price target on the biopharmaceutical company’s stock. Zacks Investment Research‘s price objective suggests a potential upside of 12.02% from the company’s previous close.
According to Zacks, “Albireo Pharma, Inc. is a biopharmaceutical company. It focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo Pharma Inc., formerly known as BIODEL INC., is based in Boston, United States. “
Several other analysts have also recently commented on ALBO. Wedbush restated a “buy” rating on shares of Albireo Pharma in a report on Wednesday, January 3rd. Cowen reaffirmed a “buy” rating on shares of Albireo Pharma in a research note on Friday, November 17th. Roth Capital assumed coverage on Albireo Pharma in a research note on Wednesday, November 15th. They set a “buy” rating and a $92.00 price target on the stock. Needham & Company LLC reaffirmed a “buy” rating on shares of Albireo Pharma in a research note on Thursday, October 26th. Finally, ValuEngine lowered Albireo Pharma from a “hold” rating to a “sell” rating in a research note on Monday, October 2nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company’s stock. Albireo Pharma has a consensus rating of “Buy” and an average price target of $54.50.
Albireo Pharma (NASDAQ:ALBO) last issued its quarterly earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.73) EPS for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.12. sell-side analysts predict that Albireo Pharma will post -3.42 EPS for the current fiscal year.
In other news, major shareholder Plc Astrazeneca sold 500,000 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $21.40, for a total value of $10,700,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 22.30% of the stock is owned by company insiders.
ILLEGAL ACTIVITY WARNING: This story was published by BBNS and is the property of of BBNS. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://baseballnewssource.com/markets/albireo-pharma-albo-raised-to-buy-at-zacks-investment-research/1818984.html.
Albireo Pharma Company Profile
Biodel Inc is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.